Mark T. Esser

14.5k total citations · 4 hit papers
100 papers, 6.4k citations indexed

About

Mark T. Esser is a scholar working on Epidemiology, Infectious Diseases and Immunology. According to data from OpenAlex, Mark T. Esser has authored 100 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Epidemiology, 32 papers in Infectious Diseases and 23 papers in Immunology. Recurrent topics in Mark T. Esser's work include Respiratory viral infections research (35 papers), Cervical Cancer and HPV Research (24 papers) and Pneumonia and Respiratory Infections (17 papers). Mark T. Esser is often cited by papers focused on Respiratory viral infections research (35 papers), Cervical Cancer and HPV Research (24 papers) and Pneumonia and Respiratory Infections (17 papers). Mark T. Esser collaborates with scholars based in United States, United Kingdom and Netherlands. Mark T. Esser's co-authors include Eliav Barr, Janine T. Bryan, Tonya Villafana, Filip Dubovsky, Frank J. Taddeo, Heather L. Sings, Therese Takas, Carlos Sattler, M. Pamela Griffin and Narendra Chirmule and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Mark T. Esser

98 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases

2007 1.4k citations Janine T. Bryan, Mark T. Esser et al. profile →
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

2020 456 citations M. Pamela Griffin, Therese Takas et al. profile →
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

2022 127 citations Hugh Montgomery, Richard Hobbs et al. profile →
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants

2023 70 citations Deidre Wilkins, Yue Chang et al. profile →

Peers

Countries citing papers authored by Mark T. Esser

Since Specialization

Citations

This map shows the geographic impact of Mark T. Esser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark T. Esser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark T. Esser more than expected).

Fields of papers citing papers by Mark T. Esser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark T. Esser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark T. Esser. The network helps show where Mark T. Esser may publish in the future.

Co-authorship network of co-authors of Mark T. Esser

This figure shows the co-authorship network connecting the top 25 collaborators of Mark T. Esser. A scholar is included among the top collaborators of Mark T. Esser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark T. Esser. Mark T. Esser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY) 2024 ·Clinical Infectious Diseases ·Douglas Arbetter, Vancheswaran Gopalakrishnan, Anastasia A. Aksyuk, (unknown), Yue Chang, Ron Dagan, Mark T. Esser, Laura L. Hammitt, Vaishali S. Mankad, Xavier Sáez‐Llorens, D. T. Shen, Amanda Leach, Elizabeth J. Kelly, Tonya Villafana, Deidre Wilkins	6
2	Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial 2024 ·Infectious Diseases and Therapy ·Richard Hobbs, Hugh Montgomery, Francisco Padilla, Jesus Abraham Simón Campos, (unknown), (unknown), Alexandre Kiazand, Katie Streicher, Nuria Martinez-Alier, Taylor S. Cohen, Mark T. Esser	1
3	Serum AZD7442 (tixagevimab–cilgavimab) concentrations and in vitroIC₅₀ values predict SARS‐CoV‐2 neutralising antibody titres 2024 ·Clinical & Translational Immunology ·Lindsay E. Clegg, (unknown), Samuel A. Matthews, Tom White, (unknown), S. Thomas, Kevin M. Tuffy, Mats Någård, Mark T. Esser, Katie Streicher, Taylor S. Cohen, Anastasia A. Aksyuk	2
4	Mixed strain pathogen populations accelerate the evolution of antibiotic resistance in patients 2023 ·Nature Communications ·Julio Diaz Caballero, Rachel M. Wheatley, Natalia Kapel, Carla López-Causapé, (unknown), (unknown), Liam P. Shaw, (unknown), Claudia Recanatini, Basil Britto Xavier, Leen Timbermont, Jan Kluytmans, Alexey Ruzin, Mark T. Esser, Surbhi Malhotra‐Kumar, Antonio Oliver, R. Craig MacLean	37
5	Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults 2023 ·The Journal of Infectious Diseases ·(unknown), Muna Albayaty, Dennis Brooks, Rosalinda H. Arends, (unknown), Anastasia A. Aksyuk, Jérôme Bouquet, Cecil Chen, (unknown), Robert Kubiak, Venkatesh Pilla Reddy, (unknown), Katie Streicher, Alison Templeton, Mark T. Esser	11
6	Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma 2022 ·Clinical Cancer Research ·Charu Aggarwal, Nabil F. Saba, Alain P. Algazi, Ammar Sukari, Tanguy Y. Seiwert, Missak Haigentz, Mercedes Porosnicu, Marcelo Bonomi, Jean Boyer, Mark T. Esser, Lily Cheng, Sonia Agrawal, Emily C. Jennings, Nicholas M. Durham, (unknown), (unknown), (unknown), (unknown), (unknown), Rakesh Kumar	26
7	Gut to lung translocation and antibiotic mediated selection shape the dynamics of Pseudomonas aeruginosa in an ICU patient 2022 ·Nature Communications ·Rachel M. Wheatley, Julio Diaz Caballero, (unknown), (unknown), (unknown), Natalia Kapel, Claudia Recanatini, Leen Timbermont, Jan Kluytmans, Mark T. Esser, Alícia Lacoma, Cristina Prat, Antonio Oliver, Samir Kumar‐Singh, Surbhi Malhotra‐Kumar, R. Craig MacLean	42
8	Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults 2019 ·Human Vaccines & Immunotherapeutics ·Adriana Weinberg, Stacie Lambert, Jennifer Canniff, Yu Li, Nancy Lang, Mark T. Esser, Judith Falloon, Myron J. Levin	4
9	Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults 2016 ·Antimicrobial Agents and Chemotherapy ·M. Pamela Griffin, Anis A. Khan, Mark T. Esser, Kathryn Jensen, Therese Takas, Martin Kankam, Tonya Villafana, Filip Dubovsky	113
10	The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public–Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia: Table 1. 2016 ·Clinical Infectious Diseases ·Bruno François, Jean Chastre, (unknown), Pierre‐François Laterre, Antoní Torres, Miguel Sánchez, Mark T. Esser, Brian Bishop, Marc J. M. Bonten, (unknown), Hasan S. Jafri	17
11	Comparison of Antibody Responses to Human Papillomavirus Vaccination as Measured by Three Assays 2014 ·Frontiers in Oncology ·Hilary A. Robbins, Troy J. Kemp, Carolina Porras, Ana Cecilia Rodríguez, Mark Schiffman, Sholom Wacholder, Paula González, John T. Schiller, Douglas R. Lowy, Sylviane Poncelet, Mark T. Esser, Katie Matys, Allan Hildesheim, Lígia A. Pinto, Rolando Herrero, Mahboobeh Safaeian	21
12	Safety and immunogenicity of a live attenuated intranasal vaccine against respiratory syncytial virus in healthy RSV seronegative children 5 to 24 months of age. 2013 ·PLoS ONE ·Elissa Malkin, Ram Yogev, Nazha Abughali, Joseph Sliman, (unknown), (unknown), C. Yang, (unknown), Mark T. Esser, Roderick S. Tang, Filip Dubovsky	6
13	Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old 2010 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Myron J. Levin, Anna‐Barbara Moscicki, Lin‐Ye Song, Terrence Fenton, William A. Meyer, Jennifer S. Read, Edward Handelsman, Barbara F. Nowak, Carlos Sattler, Alfred J. Saah, David Radley, Mark T. Esser, Adriana Weinberg	133
14	Evolution of type-specific immunoassays to evaluate the functional immune response to GARDASIL^®, a vaccine for Human Papillomavirus types 16, 18, 6, and 11 2008 ·Human Vaccines ·Judith F. Smith, (unknown), Mark T. Esser, Martha Brown, Janine T. Bryan	41
15	Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics 2007 ·Acta Obstetricia Et Gynecologica Scandinavica ·(unknown), (unknown), Heather L. Sings, (unknown), Jennifer Turpin, L. Joseph Su, (unknown), (unknown), (unknown), (unknown), Christine M. Roberts, (unknown), (unknown), Finn Egil Skjeldestad, (unknown), (unknown), (unknown), (unknown), (unknown), Mark T. Esser, Kai-Li Liaw	34
16	A novel chemistry for conjugating pneumococcal polysaccharides to Luminex microspheres 2006 ·Journal of Immunological Methods ·(unknown), (unknown), Narendra Chirmule, Mark T. Esser	64
17	Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant 2005 ·PubMed ·(unknown), W.L. McClements, Kathrin U. Jansen, Mark T. Esser	44
18	Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay 2004 ·Journal of Immunological Methods ·(unknown), Antonello Pessi, Elisabetta Bianchi, Gennaro Ciliberto, William A. Schleif, (unknown), Renee Danzeisen, Romas Geleziunas, Michael D. Miller, Debra M. Eckert, David Bramhill, Joseph G. Joyce, James C. Cook, (unknown), John W. Shiver, Emilio A. Emini, Mark T. Esser	29
19	Memory T cells and vaccines 2003 ·Vaccine ·Mark T. Esser, Rocio D. Marchese, Lisa Kierstead, Lynda Tussey, Fubao Wang, Narendra Chirmule, Michael W. Washabaugh	147
20	Distinct T cell receptor signaling requirements for perforin- or FasL-mediated cytotoxicity. 1996 ·The Journal of Experimental Medicine ·Mark T. Esser, Balasubramanian Krishnamurthy, V L Braciale	63

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact